Japan has been a leader in regenerative medicine research for many years and, since the introduction of new regulations governing approval in November 2014, possesses one of the fastest approvals systems in the world. The country’s scientists are now leading the way with clinical translation, for example with stem cell-based trials for Parkinson’s and macular degeneration.
For the first time, RegMedNet will be reporting from BioJapan and Regenerative Medicine Japan. In this post, Editor Freya Leask shares her highlights from the agenda.
Visit RegMedNet and Regenerative Medicine at booth R-56 to meet the editors and learn how you could publish your work with us!
|Wednesday, October 10th|
The Future of Drug Discovery Innovation (in Japanese)
Mr. George Nakayama, President
Japan Pharmaceutical Manufacturers Association (Japan)
REGENXBIO: AAV gene therapy for wet AMD and rare diseases
Mr. Andrew Yost, Vice President Corporate Development
REGENXBIO Inc. (MD, USA)
|Thursday, October 11th|
Utilization of IT/AI technology in the production process of biologics (in Japanese)
Prof. Michihiro Araki, Professor
Graduate School of Medicine, Kyoto University (Japan)
Recent Progress in iPS Cell Research and Application (in Japanese)
Prof. Shinya Yamanaka, Director/Professor
Center for iPS Cell Research and Application (CiRA), Kyoto University (Japan)
|Friday, October 12th|
Clinical Trial Results of the World’s First iPSC-derived MSC Therapeutic Product
Dr. Ross Macdonald, Managing Director and Chief Executive Officer
Cynata Therapeutics Limited (VIC, Australia)
(Read our exclusive interview from the World Stem Cell Summit)
Are you attending BioJapan and Regenerative Medicine Japan? Visit us at booth R-56!